Advertisement

Topics

Antex Biologics Incorporated Company Profile

20:28 EDT 22nd September 2017 | BioPortfolio

Antex Biologics is a biopharmaceutical company dedicated to the discovery, development and commercialization of products to prevent and treat infectious diseases and related disorders.

Location

300 Professional Drive
Gaithersburg
MD
20879
United States of America

Contact

Phone: 301 590 0129
Fax: 301 590 1251
Email: info@antexbiologics.com


News Articles [572 Associated News Articles listed on BioPortfolio]

Publication of the Securities Note Having Obtained Visa No. 17-297 of the AMF in Connection with the Capital Increase of GenSight Biologics

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN. Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), ("GenSight Biologics...

Heat Biologics, Inc.: Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics

DURHAM, NC / ACCESSWIRE / July 3, 2017 / Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...

Samsung Bioepis Forms Novel Biologics JV with Takeda Pharma

Samsung Bioepis, a division of Samsung Biologics, announced a joint venture with Japan's Takeda Pharma to develop novel biologic drugs. The JV's first project will be TAK-671, a candidate aimed at sev...

Heat Biologics, Inc.: Heat Biologics to Present Poster at 2017 ASCO Annual Meeting

DURHAM, NC / ACCESSWIRE / May 30, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...

Heat Biologics, Inc.: Heat Biologics Appoints Damien Hallet as Vice President of CMC Development

DURHAM, NC / ACCESSWIRE / July 3, 2017 / Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...

Samsung Bioepis and Takeda enter biologics co-development deal

Samsung Bioepis Co. Ltd., a joint venture formed by Samsung BioLogics and Biogen Inc., and Takeda Pharmaceutical Co. Ltd. entered an agreement to co-fund and co-develop biologics for diseases of unmet...

CMC Biologics, Trellis BioScience in Development and Mfg. Pact

CMC Biologics will use CHEF1 Expression Platform and Multi-column Continuous Chromatography Technology

Sanofi continues biologics push, building on recent approvals

The French drugmaker expects to invest €600 million a year in biologics production over the next several years. 

PubMed Articles [110 Associated PubMed Articles listed on BioPortfolio]

Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.

Biologic disease-modifying anti-rheumatic drugs (DMARDs: referred to as biologics) are effective in treating rheumatoid arthritis (RA), however there are few head-to-head comparison studies. Our syste...

Prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study.

Biologics are usually licensed according to the "one dose fits all" principle. It is therefore suspected that a significant number of psoriasis patients are overtreated. However, evidence for successf...

Biosimilars: biologics that meet patients' needs and healthcare economics.

Biologics have revolutionized medical care, yet uniform access to these effective medicines remains difficult due to the increasing costs of healthcare. As patent exclusivity on the early biologics wa...

The expanding field of biologics in the management of chronic urticaria.

Chronic urticaria (CU) is the occurrence of urticaria with or without angioedema for at least 6 weeks. Management has traditionally involved antihistamines as first-line therapy with various alternati...

Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: A case report.

There are roughly 5 to 10 million persons infected with human T-lymphotropic virus type 1 (HTLV-1) worldwide, and the safety of treating this population with biologics remains poorly understood.

Clinical Trials [60 Associated Clinical Trials listed on BioPortfolio]

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity

Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.

Companies [269 Associated Companies listed on BioPortfolio]

Antex Biologics Incorporated

Antex Biologics is a biopharmaceutical company dedicated to the discovery, development and commercialization of products to prevent and treat infectious diseases and related disorders.

Burst Biologics

Burst Biologics is a rapidly growing Biotechnology Company and federally registered tissue bank located in Boise, Idaho. Burst Biologics is a developer of effective tissue process...

MSD Biologics (UK) Limited

Avecia Biologics was acquired in February 2010 by MSD, the UK subsidiary of Merck & Co Inc, the world’s second largest pharmaceutical company. MSD Billingham is one of the world's leading contract ...

Precision Biologics, Inc.

Founded in February 2012 and commencing business in late September 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic ...

GT Biologics

GT Biologics is focused on the research and development of Live Biotherapeutics (LBPs) for the treatment of autoimmune diseases. GT Biologics aim to deliver a new class of medicine based on the po...

More Information about "Antex Biologics Incorporated" on BioPortfolio

We have published hundreds of Antex Biologics Incorporated news stories on BioPortfolio along with dozens of Antex Biologics Incorporated Clinical Trials and PubMed Articles about Antex Biologics Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Antex Biologics Incorporated Companies in our database. You can also find out about relevant Antex Biologics Incorporated Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...


Corporate Database Quicklinks



Searches Linking to this Company Record